BioWorld Asia

April 27, 2005

TKT Absorbed For $1.6B As Shire Fattens Pipeline

In what could be the largest acquisition of 2005 - and certainly the largest so far - Shire Pharmaceuticals Group plc has nabbed Transkaryotic Therapies Inc. in a deal worth $1.6 billion. (BioWorld International) Read More

£32.8M For Alizyme Earmarked For Renzapride, Cetilistat Work

Blocking Toxins Could Defeat Bacterial Antibiotic Resistance

Genmab Moves Zanolimumab Into Lymphoma Pivotal Study

Tight Agrobiotech Rulings Provoke German Lawsuit

Cash Squeeze Could Hamper Finnish Personalized Medicine

Microdosing Guidelines From FDA Might Reduce Time, Waste

Europe Pressures Syngenta On Testing, Containing Bt10

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...